Ocular Therapeutix News and Activities
Presence
Ocular Therapeutix develops eye care medicines and drug delivery products. Its treatments support eye surgeons, ophthalmologists, and patients with retinal diseases, post-surgery inflammation, and dry eye conditions.
Ocular Therapeutix products and services overview:
- Eye care medicines
- Drug delivery systems
- Retinal disease therapy
- Post surgery care
- Dry eye care
Revenue: ~$56 million
Employees: 270
Headquarters: Bedford, United States (USA)
Ocular Therapeutix is one of the...
Ocular Therapeutix is a company listed under the stock ticker OCUL (US).
Executives
View the org chart displaying its 26 main executives
Most searched biographies at Ocular Therapeutix
- Pravin Dugel, Director, Executive Chairman, President and Chief Ex...
- Adrienne Graves, Director
- Charles Warden, Lead Independent Director
Popular executive movements at Ocular Therapeutix
- David Robinson has joined the company as Global Chief Commercial Officer (posted on January 21 2026).
Create your alert
to follow the executive moves at Ocular Therapeutix.
Biotechnology
Ocular Therapeutix has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Ocular Therapeutix
- Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces Appointment of New Board Member | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases | Ocular Therapeutix, Inc.
- View more press releases Close
Social media about Ocular Therapeutix
- Ocular Therapeutix on Wikipedia, Google News & Yahoo Finance
- Ocular Therapeutix on LinkedIn, X (Twitter) & YouTube
